Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness
Rhea-AI Summary
Obagi Medical (NASDAQ: WALD) launched NU-GEN™ Cellular Renewal Serum on March 24, 2026, a 1oz/30ml topical formula priced at $175 that pairs NAD+ with NMN and niacinamide to address nine visible signs of skin aging.
Clinical results cited include up to six years of visible age reversal, 51% improvement in tone evenness, 30% reduction in fine lines, and rapid hydration gains within 30 minutes.
Positive
- Clinically shown to visibly rewind skin’s age up to six years
- 51% improvement in skin tone evenness reported in clinical studies
- 30% reduction in visible fine lines and wrinkles in trials
- 42% increase in skin hydration within 30 minutes in testing
- Formulation delivers NAD+ with NMN and niacinamide via proprietary AGE CTRL Complex
Negative
- Retail price set at $175 for a 1oz / 30ml bottle
- Product sold through professional channels and direct online partners only
- Recommended twice-daily application may increase ongoing consumer cost
News Market Reaction – WALD
In the Mar 24 session, WALD declined 7.38%, reflecting a notable negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | ALOHA collaboration | Positive | -8.3% | ProMD Health joins ALOHA Program to generate real-world data for MagIQ. |
| Mar 13 | Earnings results | Positive | +8.2% | FY2025 and Q4 results with $272.1M revenue and improved balance sheet. |
| Mar 11 | Earnings date | Neutral | -4.0% | Announcement of Q4/FY2025 earnings release date without conference call. |
| Feb 27 | ALOHA collaboration | Positive | -0.6% | Schweiger Dermatology collaboration to run ALOHA Phase 4 and real-world study. |
| Feb 25 | ALOHA collaboration | Positive | -2.3% | It’s a Secret Med Spa joins ALOHA to provide real-world MagIQ evaluation data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Obagi/Waldencast news has often seen negative price reactions, with only the latest earnings release aligning positively with seemingly constructive announcements.
Over the last month, WALD issued several Obagi-focused updates and financial results. Collaborations in the ALOHA Program on Feb 25, Feb 27, and Mar 19 sought to build real‑world evidence for Obagi® saypha® MagIQ™, yet 24‑hour moves were negative in each case. In contrast, Q4 and FY 2025 earnings on Mar 13 showed $272.1M FY revenue and improved leverage, and the stock rose 8.22%. Today’s NU-GEN™ launch continues Obagi’s product innovation narrative within WALD’s portfolio.
Key Terms
nad+ medical
nmn medical
niacinamide medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin’s age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously.
At the core of the formula is Obagi’s proprietary AGE CTRL™ Complex, a scientifically advanced blend that delivers NAD+ along with its essential precursors, NMN and Niacinamide. This synergistic complex targets the leading cause of skin aging, supporting the skin’s longevity pathways – addressing visible skin damage, restoring skin health, and a more youthful appearance. As natural NAD+ levels decline with age, this synergistic complex helps replenish diminished NAD+ within skin cells, supports skin’s natural cell energy production and natural cellular functions, promoting skin cell renewal. This advanced approach is engineered for precise delivery with enhanced absorption, helping address multiple early and visible hallmarks of aging, promoting longevity, and visibly rewinding the appearance of skin’s age.
“NU-GEN represents a significant step forward in longevity-focused skincare and builds on Obagi’s longstanding commitment to breakthrough innovation,” said Justin Giouzepis, Chief Marketing Officer. “We are one of the only brands, globally, that were able to formulate with NAD+ directly, which is notoriously a difficult molecule to stabilize and deliver effectively. By overcoming those challenges, we’ve created a clinically backed and unique formula that delivers NAD+, helping support skin cellular energy and resilience for healthier, stronger and younger looking skin.”
In clinical studies, NU-GEN was proven to deliver visible improvements across the nine hallmarks of skin aging, including uneven skin tone, visible imperfections, sagging skin, visible fine lines and wrinkles, skin dullness, visible redness, skin smoothness, barrier strength, and hydration levels.(1)(2)(3) Results demonstrated a
“By combining NAD+ with its precursors, NMN and Niacinamide, NU-GEN supports the skin’s natural ability to help replenish this essential coenzyme at a skin cellular level,” said Dr. Suzan Obagi, Chief Medical Director. “This comprehensive approach allows us to address multiple signs of aging simultaneously, delivering measurable, clinically validated improvements in overall skin health and appearance.”
Representing a new era in longevity-driven skincare, NU-GEN moves beyond treating surface-level symptoms to help restore visible youthfulness from the source. NU-GEN Cellular Renewal Serum features a lightweight, fast-absorbing, non-greasy formula housed in a 1oz / 30ml airless pump to preserve potency. Designed for all skin types and positioned as the foundational serum and power supply behind other treatments, it should be applied twice daily, morning and evening, to clean, dry skin as the first step after cleansing and toning for optimal results.
NU-GEN Cellular Renewal Serum is now available for
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
(1) Results based on a 2025 12-week aging clinical test. (2) Results based on a 2025 12-week blemish-prone clinical test. (3) Results based on a 2025 48-hour hydration clinical test.
Data on file at Obagi Cosmeceuticals LLC. Individual results may vary.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fa49dced-fa33-467c-9066-abc8a626e097
